Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents

AIDS

Volumn 23, Issue 4, 2009, Pages 437-446

  Coyne, Katherine M ^a   Pozniak, Anton L ^a   Lamorde, Mohammed ^b   Boffito, Marta ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b MAKERERE UNIVERSITY   (Uganda)

Author keywords

Antiretroviral agents; Antitubercular agents; Drug interactions; Multidrug resistant tuberculosis; Mycobacterium tuberculosis

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIRETROVIRUS AGENT; ATAZANAVIR; CLOFAZIMINE; CYCLOSERINE; DARUNAVIR; EFAVIRENZ; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; LINEZOLID; MACROLIDE; MOXIFLOXACIN; NEVIRAPINE; POLYPEPTIDE; PROTEINASE INHIBITOR; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SPARFLOXACIN; STREPTOMYCIN; TENOFOVIR; THIOAMIDE; TIPRANAVIR; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

AGGRESSION; ANXIETY; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; CONVULSION; DEPRESSION; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; EDITORIAL; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIVER TOXICITY; NEPHROTOXICITY; OPTIC NERVE DISEASE; OTOTOXICITY; PARANOIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSYCHOSIS; RASH; SIDE EFFECT; SUICIDAL IDEATION; TUBERCULOSIS; VIRUS REPLICATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; DRUG INTERACTIONS; HUMANS; TUBERCULOSIS;

EID: 62349084623     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328326ca50     Document Type: Editorial

References (72)

1. UNAIDS. AIDS Epidemic Update 2007. Geneva: World Health Organisation; 2007.
2. World Health Organisation. Global Tuberculosis Control 2008. Surveillance, planning, financing. Geneva: World Health Organisation; 2008.
3. White VL, Moore-Gillon J. Resource implications of patients with multidrug resistant tuberculosis. Thorax 2000; 55:962-963.
4. Rajbhandary SS, Marks SM, Bock NN. Costs of patients hospitalized for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2004; 8:1012-1016.
5. Ghandi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1554-1556.
6. de Maat MM, Ekhart GC, Huitema AD, Koks CH, Mulder JW, Beijnen JH. Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet 2003; 42:223-282.
7. Barry M, Mulcahy F, Merry C, Gibbons S, Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999; 36:289-304.
8. Kakuda TN, Scholler-Gyure M, Peelers M, Vingerhoets J, Corbett C, Woodfall BJ, et al. Pharmacokinetics and pharmacodynamics of TMC125 in HIV-infected patients with nonnucleoside reverse transcriptase inhibitor and protease inhibitor resistance: TMC125-C223. 14th Conference on Retrovirus and Opportunistic Infections; Los Angeles, 2007.
9. van der Lee MJ, Dawood L, ter Hofstede HJ, de Craaf-Teulen MJ, van Ewijk-Beneken Kolmer EW, Caliskan-Yassen N, et al. Lopinavir/ritonavir reduces Iamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther 2006; 80: 159-168.
10. Ho YI, Chan CY, Cheng AF. In-vitro activities of aminoglycoside- aminocyclitols against mycobacteria. J Antimicrob Chemother 1997; 40:27-32.
11. Gaillard J-L, Silly C, Le Masne A, Mahut B, Lacaille F, Cheron G, et al. Cerebrospinal fluid penetration of amikacin in children with community-acquired bacterial meningitis. Antimicrob Agents Chemother 1995; 39:253-255.
12. McCracken GH. Aminoglycoside toxicity in infants and children. Am J Med 1986; 80 (Suppl 6B):172-178.
13. Brummett RE, Fox KE. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother 1989; 33:797-800.
14. Ziganshina LE, Vizel AA, Squire SB. Fluoroquinolones for treating tuberculosis. In: The Cochrane Database of Systematic Reviews; Issue 3. Chichester: John Wiley; 2005.
15. Vance-Bryan K, Guay DR, Rotschafer JC. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet 1990; 19:434-461.
16. Lamp KC, Bailey EM, Rybak MJ. Ofloxacin clinical pharmacokinetics. Clin Pharmacokinet 1992; 22:32-46.
17. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997; 32:101-119.
18. Shimada J, Nogita T, Ishibashi Y. Clinical pharmacokinetics of sparfloxacin. Clin Pharmacokinet 1993; 25:358-369.
19. Anson BD, Weaver JGR, Ackerman MJ, Akinsete O, Henry K, January CT, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet 2005; 365:682-686.
20. Castillo R, Pedalino RP, El-Sherif N, Turitto G. Efavirenz-associated QT prolongation and torsade de pointes arrhythmia. Ann Pharmacother 2002; 36:1006-1008.
21. Davis R, Bryson HM. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994; 4:677-700.
22. Aminimanizani A, Beringer P, Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibactenals. Clin Pharmacokinet 2001; 40:169-187.
23. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 (Suppl B):83-90.
24. Weiner M, Burman W, Luo CC, Peloquin CA, Engle M, Goldberg S, et al. Effects of rifampicin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother 2007; 51:2861-2866.
25. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008; 42:1048-1059.
26. Jenner PJ, Smith SE. Plasma levels of ethionamide and prothionamide in a volunteer following intravenous and oral dosages. Lepr Rev 1987; 58:31-37.
27. Jenner PJ, Ellard GA, Gruer PJK, Aber VR. A comparison of the blood levels and urinary excretion of ethionamide and prothionamide in man. J Antimicrob Chemother 1984; 13: 267-277.
28. Berning SE, Peloquin CA. Antimicrobial agents: ethionamide. In: Yu VL, Merigan TC, Barriere S, White NJ, editors. Antimicrobial chemotherapy and vaccines. Baltimore, MD: Williams and Wilkins; 1998. pp. 650-654.
29. Pattyn SR, Janssens L, Bourland J, Saylan T, Davies E M, Grillone S, et al. Hepatotoxicity of the combination of rifampin-ethionamide in the treatment of multibacillary leprosy. Int J Lepr 1984; 52:1-6.
30. Cartel J-L, Millan J, Guelpa-Lauras CC, Grosset JH. Hepatitis in leprosy patients treated by a daily combination of dapsone, rifampin, and a thioamide. Int I Lepr 1983; 51:461-465.
31. Brück S, Witte S, Brust J, Schuster D, Mosthaf F, Procaccianti M, et al. Hepatotoxicity in patients prescribed efavirenz or nevirapine. Eur J Med Res 2008; 13:343-348.
32. Vispo E. Warning on hepatotoxicity of darunavir. AIDS Rev 2008; 10:63.
33. Dong BJ, Cocohoba JM. Tipranavir: a protease inhibitor for HIV salvage therapy. Ann Pharmacother 2006; 40:1311-1321.
34. Arendt G, de Nocker D, von Giesen HJ, Nolting T. Neuropsychiatry side effects of efavirenz therapy. Expert Opin Drug Saf 2007; 6:147-154.
35. Lansdown FS, Beran M, Litwak T. Psychotoxic reaction during ethionamide therapy. Am Rev Respir Dis 1967; 93: 1053-1055.
36. Berning SE, Peloquin CA. Antimicrobial agents: cycloserine. In: Yu VL, Merigan TC, Barriere S, White NJ, editors. Antimicrobial chemotherapy and vaccines. Baltimore, MD: Williams and Wilkins; 1998. pp. 638-642.
37. Peloquin CA. Antituberculosis drugs: pharmacokinetics. In: Heifets LB, editor. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press; 1991. pp. 89-122.
38. Verbist L. Mode of action of antituberculous drugs (Part I). Medicon Int 1974; 3:11-23.
39. Verbist L. Mode of action of antituberculous drugs (Part II). Medicon Int 1974; 3:3-17.
40. Spector R, Lorenzo WV. The active transport of para-aminosalicyclic acid from the cerebrospinal fluid. J Pharmacol Exp Ther 1973; 185:642-648.
41. Berning SE, Peloquin CA. Antimicrobial agents: para-aminosalicylic acid. In: Yu VL, Merigan TC, Barriere S, White NJ, editors. Antimicrobial chemotherapy and vaccines. Baltimore, MD: Williams and Wilkins; 1998. pp. 663-668.
42. Way EL, Smith PK, Howie DL. The absorption, distribution, excretion and fate of para-aminosalicylic acid. J Pharmacol Exp Ther 1948; 93:368-382.
43. Domagk G, Behnish R, Mietasch F, Schmidt H. Uber eine neue gegen tuberkelbazillon in vitro wirksame berbindungs klasse. Naturwiss 1946; 33:315.
44. Chintu C, Luo C, Bhat C, Raviglione M, DuPont H, Zumla A. Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-1. Arch Dis Child 1993; 68:665-668.
45. Nunn P, Kibuga D, Cathua S, Brindle R, Imalingat A, Wasunna K. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet 1991; 337:627-630.
46. Arbiser JL, Moschella SL. Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol 1995; 32:241-247.
47. Holdiness MR. Clinical pharmacokinetics of clofazimine: a review. Clin Pharmacokinet 1989; 16:74-85.
48. Mehta J, Gandhi IS, Sane SB, Wamburkar MN. Effect of clofazimine and dapsone on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases. Lepr Rev 1986; 57 (Suppl 3):67-76.
49. Nadler JP, Berger J, Nord JA, Cofsky R, Saxena M. Amoxicillinclavulanic acid for treating drug-resistanct Mycobacterium tuberculosis. Chest 1991; 99:1025-1026.
50. Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 1999; 37:385-398.
51. Petty B, Polis M, Haneiwich S, Dellerson M, Craft JC, Chaisson R. Pharmacokinetic assessment of clarithromycin plus zidovudine in HIV patients [Abstract 24]. In: Programs and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1192 Washington DC: American Society of Microbiology, p. 114.
52. Vance E, Watson-Bitar M, Gustavson L, Kazanjian P. Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. Antimicrob Agents Chemother 1995; 39:1355-1360.
53. Pol is MA, Piscitelli SC, Vogel S, Witebsky FG, Conville PS, Petty B, et al. Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997; 41:1709-1714.
54. Quellet D, Hsu A, Granneman GR, Carlson G, Cavanaugh J, Guenther H, et al. Pharmacokinetic interaction between ritonavir and clarithromycin. Clin Pharmacol Ther 1998; 64:355-362.
55. Gillum JG, Bruzzese VL, Israel DS, Kaplowitz LG, Polk RE. Effect of clarithromycin on the pharmacokinetics of 2',3'-dideoxyinosine in patients who are seropositive for human immunodeficiency virus. Clin Infect Dis 1996; 22:716-718.
56. Kuper JI, D'Aprile M. Drug-drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet 2000; 39:203-214.
57. Lalak NJ, Morris DL. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet 1993; 25:370-374.
58. Luke DR, Foulds G, Cohen SF, Levy B. Safety, toleration, and pharmacokinetics of intravenous azithromycin. Antimicrob Agents Chemother 1996; 40:2577-2581.
59. Rapp RP. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drug interactions. Ann Pharmacother 1998; 32:785-793.
60. Benedek IH, Joshi A, Fiske WD, White SJ, Jobes JL, Joseph JL, et al. Pharmacokinetic (PK) interaction studies in healthy volunteers with efavirenz (EFV) and the macrolide antibiotics, azithromycin (AZM) and clarithromycin (CLR). Program Abstr 5th Conf Retrovir Oppor Infect Conf Retrovir Oppor Infect 5th 1998 Chic III. 1998 Feb 1-5; 5th: 144 [abstract no. 347].
61. Amsden GW, Nafziger AN, Foulds G, Cabelus LJ. A study of the pharmacokinetics of azithromycin and nelfinavir when coad-ministered in healthy volunteers. J Clin Pharmacol 2000; 40:1522-1527.
62. Amsden G, Flaherty J, Luke D. Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients. J Clin Pharmacol 2001; 41:210-216.
63. Fortun J, Martin-Davila P, Navas E, Perez-Elias MJ, Cobo J, Tato M, et al. Linezolid for the treatment of multidrug resistant tuberculosis. J Antimicrob Chemother 2005; 56: 180-185.
64. Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. JAMA 2001; 285:1291.
65. Bishop E, Melvani S, Howden BP, Charles PG, Grayson ML. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicmb Agents Chemother 2006; 50:1599-1602.
66. De Vriese AS, Coster RV, Smet J, Seneca S, Lovering A, Van Haute LL. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006; 42:1111-1117.
67. Garrabou G, Soriano A, Lopez S, Guallar JP, Cirait M, Villarroya F. Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob Agents Chemother 2007; 51:962-967.
68. Rubinstein E, Isturiz R, Standiford HC, Smith LG, Oliphant TH, Cammarata S, et al. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicmb Agents Chemother 2003; 47:1824-1831.
69. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Grampositive infections. J Antimicrob Chemother 2003; 51 (Suppl S2):ii17-ii25.
70. Stalker Dj, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42:1129-1140.
71. Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, Patientia RF, et al. Early bacterial activity and pharmacokinetics of the Diarylquinolone TMC 207 in pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52:2831-2835.
72. Hurdle JG, Lee RB, Budha NR. A microbiological assessment of novel nitrofuranylamides as antituberculous agents. J Antimicrob Chemother 2008; 62:1037-1045.